Skip to main content Accessibility help
×
Home

Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk

  • Matthew J. Ziegler (a1), Craig Freyer (a2), Daniel Landsburg (a3), David Pegues (a1) (a4), Warren Bilker (a5), Rebecca Hirsh (a3), Colleen Kucharczuk (a3), Cheryl Gilmar (a4), Theresa Gorman (a3), Melissa Palmer (a3), Christina Harker (a3), Erin Lightheart (a6) and Jennifer H. Han (a1) (a4) (a5)...

Abstract

We implemented a guideline for appropriate acid suppressant use in hematology-oncology patients. This intervention resulted in a sustained reduction in proton pump inhibitor (PPI) use without an increase in rates of gastrointestinal bleeding. Practice guidelines are effective in reducing PPI use, which is associated with risk of Clostridioides difficile infection.

Copyright

Corresponding author

Author for correspondence: Matthew J. Ziegler, E-mail: matthew.ziegler@uphs.upenn.edu

Footnotes

Hide All

PREVIOUS PRESENTATION. The interim results of this study were presented at the Society for Healthcare Epidemiology of America conference as an oral abstract presentation on April 26, 2019, in Boston, Massachusetts.

Present affiliation: GlaxoSmithKline, Rockville, Maryland

Footnotes

References

Hide All
1. Revolinski, SL, Munoz-Price, LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis 2019;68:21442153.
2. Janarthanan, S, Ditah, I, Adler, DG, Ehrinpreis, MN. Clostridium difficile–associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:10011010.
3. Dial, S, Delaney, JA, Barkun, AN, Suissa, S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:29892995.
4. Ziegler, M, Landsburg, D, Pegues, D, et al. Clinical characteristics and outcomes of hematologic malignancy patients with positive Clostridium difficile toxin immunoassay versus polymerase chain reaction test results. Infect Control Hosp Epidemiol 2018;39:863866.
5. Wahking, RA, Steele, RL, Hanners, RE, Lockwood, SM, Davis, KW. Outcomes from a pharmacist-led proton pump inhibitor stewardship program at a single institution. Hosp Pharm 2018;53:5967.
6. Kandel, CE, Gill, S, McCready, J, Matelski, J, Powis, JE. Reducing coadministration of proton pump inhibitors and antibiotics using a computerized order entry alert and prospective audit and feedback. BMC Infect Dis 2016;16:355.
7. Kwok, CS, Arthur, AK, Anibueze, CI, Singh, S, Cavallazzi, R, Loke, YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:10111019.
8. MacLaren, R, Reynolds, PM, Allen, RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014;174:564574.
9. Sartori, S, Trevisani, L, Nielsen, I, Tassinari, D, Panzini, I, Abbasciano, V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 2000;18:463467.
10. Numico, G, Fusco, V, Franco, P, Roila, F. Proton pump inhibitors in cancer patients: how useful they are? A review of the most common indications for their use. Crit Rev Oncol Hematol 2017;111:144151.
Type Description Title
WORD
Supplementary materials

Ziegler et al. supplementary material
Ziegler et al. supplementary material

 Word (29 KB)
29 KB

Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk

  • Matthew J. Ziegler (a1), Craig Freyer (a2), Daniel Landsburg (a3), David Pegues (a1) (a4), Warren Bilker (a5), Rebecca Hirsh (a3), Colleen Kucharczuk (a3), Cheryl Gilmar (a4), Theresa Gorman (a3), Melissa Palmer (a3), Christina Harker (a3), Erin Lightheart (a6) and Jennifer H. Han (a1) (a4) (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed